BioSig Technologies, Inc. STEX Proceeds From Sale Of Common Stock Under Atthemarket Offerings Net Of Issuance Costs
Other financials
Where this comes from
Reported directly by BioSig Technologies, Inc. in its filing.
Tagged under the XBRL concept STEX:ProceedsFromSaleOfCommonStockUnderAtthemarketOfferingsNetOfIssuanceCosts.
The official record: BioSig Technologies, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioSig Technologies, Inc.'s proceeds from sale of common stock under atthemarket offerings net of issuance costs.
Connect your AI assistant and see it in context, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioSig Technologies, Inc.'s proceeds from sale of common stock under atthemarket offerings net of issuance costs?
- BioSig Technologies, Inc. (STEX) reported proceeds from sale of common stock under atthemarket offerings net of issuance costs of $3.88M in Q1 2025.